JON GAMBILL: Open Payments
NPI 1073586319 · CANYONVILLE, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$407 in 20 payments from 10 companies in 2025. Trend: 2023 $436 · 2024 $536 · 2025 $407
Food & beverage: $407
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 8 | $162 |
| ABBVIE INC. | 3 | $71 |
| GlaxoSmithKline, LLC. | 1 | $30 |
| AstraZeneca Pharmaceuticals LP | 2 | $28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 |
| Edwards Lifesciences Corporation | 1 | $22 |
| Novo Nordisk Inc | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
Products named: EVENITY, REPATHA, VRAYLAR, OTEZLA, TRELEGY ELLIPTA, MAVYRET, JARDIANCE, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve.
Industry payments across OR — which companies pay providers there.
